David McDermott, MD
Immunotherapy is at the forefront of the burgeoning treatment landscape in renal cell carincoma (RCC), according to David McDermott, MD.
For example, the FDA approved nivolumab (Opdivo) in November 2015 as a treatment for patients with metastatic RCC following prior antiangiogenic therapy. The approval was based on the phase III CheckMate-025 trial, in which nivolumab reduced the risk of death by 27% versus everolimus (Afinitor) in this setting.
As ongoing trials continue to evaluate nivolumab and other immunotherapies in RCC, oncologists are striving to tailor treatments to the right patient populations.
“We’re always trying to improve our selection of patients, coming up with predictive markers to identify who might benefit before we start any treatment,” said McDermott.